Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has provided an updated notification to the ASX on its ongoing on-market share buy-back program for its ordinary fully paid shares. The update, dated 23 March 2026, confirms that a total of 4,740,865 shares had been bought back prior to the previous trading day, with an additional 111,000 shares repurchased on the previous day.
The filing is a routine daily buy-back notification, following the company’s initial buy-back notice lodged in August 2025 and the most recent prior update on 20 March 2026. The continued execution of the on-market buy-back signals ongoing capital management activity, which may support earnings per share over time and reflects CSL’s confidence in its financial position and long-term outlook.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$155.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, best known for its plasma-derived therapies, vaccines, and other specialty biopharmaceutical products. The company focuses on treating rare and serious diseases and serves healthcare systems and patients worldwide, making its capital management decisions closely watched by investors.
YTD Price Performance: -18.74%
Average Trading Volume: 1,224,912
Technical Sentiment Signal: Sell
Current Market Cap: A$67.22B
See more insights into CSL stock on TipRanks’ Stock Analysis page.